

Pneumonia Drug Therapeutics Development and Professional Review Analysis 2017

Pneumonia Drug Pharmaceutical and Healthcare Analysis Information

PUNE, INDIA, October 13, 2017 /EINPresswire.com/ -- Summary

This report provides an overview of the pipeline landscape for pneumonia disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.

Community acquired pneumonia is pneumonia contracted by a person who has had little contact with the healthcare system, with common symptoms including cough, fever and shortness of breath. Risk factors include chronic lung disease, cigarette smoking, immune system problems and surgery.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/2385278-pneumonia-drug-development-pipeline-review-2017> □

Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted. Signs and symptoms include malaise, fever, chills, rigor, cough, dyspnea, and chest pain, but in ventilated patients, pneumonia usually manifests as worsening oxygenation and increased tracheal secretions.

Finally, ventilator associated pneumonia is pneumonia that occurs in people who are on mechanical ventilation breathing machines in hospitals. As such the disease typically affects critically ill patients and increases the risk of mortality. Signs and symptoms include fever or low body temperature, new purulent sputum and hypoxemia.

The size of these pipelines ranges from 20 products in community acquired pneumonia to 39 in hospital acquired pneumonia. Across all three of these indications bacterial targets such as DNA gyrase and ribosomal DNA are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

- Which companies are the most active within the pipeline for pneumonia therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of pneumonia?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates

and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents	4
1.1 List of Tables	5
1.2 List of Figures	7
2 Introduction	8
2.1 Pneumonia Report Coverage	8
2.2 Community Acquired Pneumonia - Overview	8
2.3 Hospital Acquired Pneumonia (HAP) - Overview	8
2.4 Ventilator Associated Pneumonia (VAP) - Overview	8
3 Therapeutics Development	9
3.1 Community Acquired Pneumonia	9
3.2 Hospital Acquired Pneumonia (HAP)	13
3.3 Ventilator Associated Pneumonia (VAP)	19
4 Therapeutics Assessment	24
4.1 Community Acquired Pneumonia	24
4.2 Hospital Acquired Pneumonia (HAP)	30
4.3 Ventilator Associated Pneumonia (VAP)	37
5 Companies Involved in Therapeutics Development	44
5.1 Community Acquired Pneumonia	44
5.2 Hospital Acquired Pneumonia (HAP)	51
5.3 Ventilator Associated Pneumonia (VAP)	64
6 Dormant Projects	75
6.1 Community Acquired Pneumonia	75
6.2 Hospital Acquired Pneumonia (HAP)	76
6.3 Ventilator Associated Pneumonia (VAP)	77
7 Discontinued Products	78
7.1 Community Acquired Pneumonia	78
7.2 Hospital Acquired Pneumonia (HAP)	78
7.3 Ventilator Associated Pneumonia (VAP)	79
8 Product Development Milestones	80
8.1 Community Acquired Pneumonia	80
8.2 Hospital Acquired Pneumonia (HAP)	95
8.3 Ventilator Associated Pneumonia (VAP)	109
9 Appendix	122
9.1 Methodology	122
...Continued	

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/2385278-pneumonia-drug-development-pipeline-review-2017> □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts> □

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.